Investment Rating - The report maintains an "Accumulate" rating for China Feihe (6186.HK) with a current price of HKD 3.68 [1] Core Insights - In 2025, China Feihe achieved revenue of CNY 18.11 billion, a year-on-year decrease of 12.7%, and a net profit attributable to shareholders of CNY 1.94 billion, down 45.7% [4][5] - The infant formula business, which accounts for 88% of total revenue, faced pressure due to declining birth rates and increased competition, resulting in a revenue decline of 16.8% [5] - Despite challenges, the company remains a market leader with a 19% market share and high brand recognition [5] - New high-end products launched in 2025 have shown promising performance and are expected to contribute to revenue growth [5][8] - The company plans to maintain a high dividend policy, distributing no less than CNY 2 billion in dividends for 2025 [7] Financial Performance Summary - Revenue and profit forecasts for 2026-2028 have been adjusted downwards due to weak demand for infant formula, with projected net profits of CNY 2.29 billion in 2026 and CNY 2.45 billion in 2027 [8][11] - The overall gross margin for 2025 was 65.0%, a decrease of 1.3 percentage points, primarily due to an increase in low-margin raw material sales [7] - The company has a strong cash flow position, with operating cash flow projected to improve in the coming years [13] Market Expansion - In 2025, overseas revenue reached CNY 230 million, with significant growth in the Canadian market, where the company received its first foreign infant formula production license [8] - Plans for 2026 include entering the U.S. and Mexican markets, further expanding North American operations [8] Valuation and Earnings Forecast - The current stock price corresponds to a price-to-earnings ratio of 13x for 2026, 12x for 2027, and 11x for 2028, indicating a favorable valuation for a leading player in the domestic milk powder industry [8][11]

Investment Rating - The report maintains a "Buy" rating for China Feihe (6186.HK) with a current price of HKD 5.87 [1] Core Views - The company achieved a revenue of CNY 20.75 billion in 2024, representing a year-on-year increase of 6.2%, and a net profit of CNY 3.57 billion, up 5.3% year-on-year. In the second half of 2024, revenue reached CNY 10.65 billion, with a year-on-year growth of 8.7%, while net profit was CNY 1.7 billion, showing a slight increase of 0.1% year-on-year [4] - The company is implementing a full-age nutrition strategy, expanding its product offerings beyond infant formula to include products for children, adults, and functional nutrition [8] Summary by Sections Financial Performance - In 2024, the company reported a gross margin of 66.3% and a net profit margin of 17.2%. The second half of 2024 saw a gross margin of 64.9% and a net profit margin of 15.9%, with a notable decline in net profit margin attributed to increased sales expenses and reduced government subsidies [6] - Revenue from infant formula products was CNY 19.06 billion in 2024, reflecting a 6.6% year-on-year increase. Other dairy products generated CNY 1.514 billion, up 6.3% year-on-year, while health products saw a decline of 25.4% to CNY 173 million [5] Strategic Initiatives - The company has launched a CNY 1.2 billion childbirth subsidy plan to attract new customers, which is expected to enhance revenue growth. Additionally, it has strengthened its presence in the Canadian market and is exploring opportunities in Southeast Asia and the Middle East [7] - The company is transitioning to a full-age nutrition model, with plans to develop products for children and adults, including a recent launch of a protein product aimed at reducing muscle loss in adults [8] Profit Forecast and Valuation - The profit forecast for 2025 has been adjusted to CNY 3.812 billion, a 4% decrease, while the 2026 forecast remains at CNY 4.141 billion. The report introduces a 2027 profit forecast of CNY 4.405 billion. The current stock price corresponds to a P/E ratio of 13x for 2025, 12x for 2026, and 11x for 2027 [8][10]